| Identification | Back Directory | [Name]
a-D-Glucopyranose,3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-4-O-phosphono-b-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-,1-(dihydrogen phosphate), sodium salt (1:4) | [CAS]
185954-98-7 | [Synonyms]
B1287
B-1287
B 1287
Eritorane
eritoran tetrasodium
a-D-Glucopyranose,3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-4-O-phosphono-b-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-,1-(dihydrogen phosphate), sodium salt (1:4) | [Molecular Formula]
C66H122N2Na4O19P2 | [MOL File]
185954-98-7.mol | [Molecular Weight]
1401.58 |
| Hazard Information | Back Directory | [Uses]
Treatment of sepsis and other
diseases due to reaction to bacterial endotoxin (endotoxin
antagonist). | [Definition]
ChEBI: Eritoran tetrasodium is an organic sodium salt which is the tetrasodium salt of eritoran. It contains an eritoran(4-). | [in vivo]
Eritoran tetrasodium (233 μg/mouse; i.p.; 10 days) protects mouse from EBOV lethal infection, results 70% survived until the end of the study[1].
Eritoran tetrasodium (2 μL of 1.1 mg/mL, corneal infusion) inhibits LPS (HY-D1056) -induced corneal inflammation in mice[2].
| Animal Model: | C57BL/6J mice challenged with lethal EBOV[1] | | Dosage: | 233 μg/mouse | | Administration: | Intraperitoneal injection; 10 days | | Result: | Reduced granulocytosis and results in a higher percentage of activated CD11b+ Ly6G/Ly6C+ neutrophils.
Dramatically reduced the levels of IFN-γ-secreting CD8+ and CD4+ T cells and IL-17A-secreting CD4+ T cells.
|
|
|
|